Abeona Therapeutics 将来の成長

Future 基準チェック /56

Abeona Therapeuticsは、61.8%と65.5%でそれぞれ年率61.8%で利益と収益が成長すると予測される一方、EPSはgrowで64%年率。

主要情報

61.8%

収益成長率

64.0%

EPS成長率

Biotechs 収益成長	28.5%
収益成長率	65.5%
将来の株主資本利益率	n/a
アナリストカバレッジ	Good
最終更新日	25 Nov 2024

今後の成長に関する最新情報

Recent updates

Here's Why We're Watching Abeona Therapeutics' (NASDAQ:ABEO) Cash Burn Situation

Aug 16

Can Abeona Therapeutics (NASDAQ:ABEO) Afford To Invest In Growth?

Mar 31

Abeona: Pivotal Data Readout EB-101 Before Year End Could Boost Shareholder Value

Oct 19

Abeona Therapeutics stock continues recent strong run, shares rise ~10%

Oct 04

Abeona Therapeutics GAAP EPS of -$2.08, revenue of $1M

Aug 11

Abeona therapeutics regains compliance with Nasdaq minimum bid price requirement

Jul 20

Abeona crashes 21% as reverse stock split takes effect

Jul 05

Here's Why Abeona Therapeutics (NASDAQ:ABEO) Must Use Its Cash Wisely

Mar 02

Here's Why Abeona Therapeutics (NASDAQ:ABEO) Can Manage Its Debt Despite Losing Money

Aug 17

Abeona Therapeutics shares rise after letter to stockholders

May 26

Despite Lacking Profits Abeona Therapeutics (NASDAQ:ABEO) Seems To Be On Top Of Its Debt

Apr 28

Independent Director Paul Mann Just Sold A Bunch Of Shares In Abeona Therapeutics Inc. (NASDAQ:ABEO)

Feb 21

How Much Did Abeona Therapeutics'(NASDAQ:ABEO) Shareholders Earn From Share Price Movements Over The Last Three Years?

Jan 19

What Kind Of Investors Own Most Of Abeona Therapeutics Inc. (NASDAQ:ABEO)?

Dec 15

業績と収益の成長予測

NasdaqCM:ABEO - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	76	-28	-22	-38	6
12/31/2025	19	-62	-30	-56	6
12/31/2024	0	-70	-67	-54	6
9/30/2024	N/A	-71	-51	-49	N/A
6/30/2024	N/A	-53	-44	-42	N/A
3/31/2024	4	-77	-41	-40	N/A
12/31/2023	4	-54	-37	-37	N/A
9/30/2023	4	-45	-42	-42	N/A
6/30/2023	4	-39	-43	-43	N/A
3/31/2023	1	-31	-42	-42	N/A
12/31/2022	1	-43	-44	-43	N/A
9/30/2022	4	-83	-63	-60	N/A
6/30/2022	4	-84	-67	-63	N/A
3/31/2022	3	-91	-70	-66	N/A
12/31/2021	3	-85	-70	-66	N/A
9/30/2021	3	-54	-38	-37	N/A
6/30/2021	10	-54	-38	-37	N/A
3/31/2021	10	-52	-37	-35	N/A
12/31/2020	10	-84	-36	-35	N/A
9/30/2020	7	-85	-49	-48	N/A
6/30/2020	N/A	-95	-57	-55	N/A
3/31/2020	N/A	-106	-67	-61	N/A
12/31/2019	N/A	-76	-69	-63	N/A
9/30/2019	0	-77	-83	-66	N/A
6/30/2019	2	-76	-74	-56	N/A
3/31/2019	2	-65	-67	-50	N/A
12/31/2018	3	-57	-59	-39	N/A
9/30/2018	3	-48	-36	-27	N/A
6/30/2018	1	-37	N/A	-25	N/A
3/31/2018	1	-33	N/A	-21	N/A
12/31/2017	1	-27	N/A	-23	N/A
9/30/2017	1	-26	N/A	-21	N/A
6/30/2017	1	-23	N/A	-18	N/A
3/31/2017	1	-22	N/A	-16	N/A
12/31/2016	1	-22	N/A	-13	N/A
9/30/2016	1	-17	N/A	-12	N/A
6/30/2016	1	-21	N/A	-11	N/A
3/31/2016	1	-18	N/A	-10	N/A
12/31/2015	1	-15	N/A	-10	N/A
9/30/2015	1	-25	N/A	-9	N/A
6/30/2015	1	-21	N/A	-6	N/A
3/31/2015	1	-30	N/A	-5	N/A
12/31/2014	1	-30	N/A	-2	N/A
9/30/2014	1	-19	N/A	-1	N/A
6/30/2014	1	-17	N/A	-2	N/A
3/31/2014	1	-3	N/A	0	N/A
12/31/2013	2	2	N/A	0	N/A

アナリストによる今後の成長予測

収入対貯蓄率: ABEOは今後 3 年間で収益性が向上すると予測されており、これは貯蓄率 ( 2.6% ) よりも高い成長率であると考えられます。

収益対市場: ABEO今後 3 年間で収益性が向上すると予想されており、これは市場平均を上回る成長と考えられます。

高成長収益: ABEO今後 3 年以内に収益を上げることが予想されます。

収益対市場: ABEOの収益 ( 65.5% ) US市場 ( 8.9% ) よりも速いペースで成長すると予測されています。

高い収益成長: ABEOの収益 ( 65.5% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: ABEOの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

Abeona Therapeutics 将来の成長

Future 基準チェック /56

主要情報

今後の成長に関する最新情報

Consensus EPS estimates fall by 14%

Consensus revenue estimates decrease by 33%, EPS upgraded

Consensus EPS estimates upgraded to US$1.36 loss

Price target decreased by 7.1% to US$19.50

Consensus revenue estimates fall by 10%

Forecast to breakeven in 2026

Recent updates

Consensus EPS estimates fall by 14%

Abeona Therapeutics Announces FDA Acceptance of BLA Resubmission of Pz-cel for the Treatment of Recessive Dystrophic Epidermolysis Bullosa

Is Abeona Therapeutics (NASDAQ:ABEO) Using Too Much Debt?

Consensus revenue estimates decrease by 33%, EPS upgraded

Abeona Therapeutics Inc. Announces Board Appointments

Independent Director notifies of intention to sell stock

Independent Director recently bought US$52k worth of stock

New major risk - Negative shareholders equity

New major risk - Shareholder dilution

Consensus EPS estimates upgraded to US$1.36 loss

Abeona Therapeutics Inc. has completed a Follow-on Equity Offering in the amount of $75.000174 million.

We're Not Very Worried About Abeona Therapeutics' (NASDAQ:ABEO) Cash Burn Rate

Price target decreased by 7.1% to US$19.50

Consensus revenue estimates fall by 10%

New major risk - Financial position

Abeona Therapeutics Inc. Provides Regulatory Update on Pz-Cel

Abeona Therapeutics Inc., Annual General Meeting, Apr 24, 2024

Full year 2023 earnings: EPS misses analyst expectations

New minor risk - Share price stability

President recently bought US$88k worth of stock

We're Not Very Worried About Abeona Therapeutics' (NASDAQ:ABEO) Cash Burn Rate

Forecast to breakeven in 2026

Abeona Therapeutics Inc. Announces FDA Accepts and Grants Priority Review for Pz-cel Biologics License Application (BLA)

Abeona Therapeutics Inc. Announces FDA Accepts and Grants Priority Review for Pz-cel Biologics License Application (BLA)

Forecast to breakeven in 2025

New minor risk - Share price stability

New minor risk - Insider selling

Abeona Therapeutics Submits Biologics License Application to U.S. FDA Seeking Priority Review and Approval of EB-101 for the Treatment of Patients with Recessive Dystrophic Epidermolysis Bullosa

Abeona Therapeutics Inc. Appoints Madhav Vasanthavada as Chief Commercial Officer

Abeona Therapeutics Announces Positive Pre-BLA Meeting with FDA for EB-101 and Plans for BLA Submission

Here's Why We're Watching Abeona Therapeutics' (NASDAQ:ABEO) Cash Burn Situation

Second quarter 2023 earnings released: US$0.92 loss per share (vs US$2.08 loss in 2Q 2022)

Abeona Therapeutics Announces Additional Phase 3 Viital Study Results for Eb-101 Presented At the International Societies for Investigative Dermatology 2023 Meeting

Can Abeona Therapeutics (NASDAQ:ABEO) Afford To Invest In Growth?

Price target increased to US$29.00

High number of new and inexperienced directors

Abeona Therapeutics Inc. announced that it expects to receive $35.000004 million in funding from Adage Capital Management, L.P., Armistice Capital LLC, EcoR1 Capital, LLC, Nantahala Capital Management, LLC, Deerfield Management Company, L.P. Series C and other investors

Consensus forecasts updated

Abeona Therapeutics Inc. announced that it expects to receive $35.000004 million in funding from Adage Capital Management, L.P., Armistice Capital LLC, EcoR1 Capital, LLC, Nantahala Capital Management, LLC, Deerfield Management Company, L.P. Series C

Abeona Therapeutics Inc. Announces Database Lock for Pivotal Phase 3 VIITAL Study of EB-101 in Patients with Recessive Dystrophic Epidermolysis Bullosa

Abeona: Pivotal Data Readout EB-101 Before Year End Could Boost Shareholder Value

Abeona Therapeutics Inc. Announces Completion of Patient Follow-up in Pivotal Phase 3 VIITAL™ Study of EB-101 in Patients with Recessive Dystrophic Epidermolysis Bullosa

Abeona Therapeutics stock continues recent strong run, shares rise ~10%

Consensus forecasts updated

Abeona Therapeutics GAAP EPS of -$2.08, revenue of $1M

Abeona Therapeutics Regains Compliance with Nasdaq Listing Requirements

Abeona therapeutics regains compliance with Nasdaq minimum bid price requirement

Abeona Therapeutics Inc., Annual General Meeting, Aug 17, 2022

Consensus forecasts updated

Abeona crashes 21% as reverse stock split takes effect

Consensus revenue estimates increase by 95%

Nasdaq Grants Second 180-Day Period to Abeona Therapeutics to Regain Compliance with Minimum Bid Price Rule

Price target decreased to US$2.00

High number of new and inexperienced directors

Consensus forecasts updated

Abeona Therapeutics Inc. Reports Goodwill Impairment Charge for the Fourth Quarter Ended December 31, 2021

Here's Why Abeona Therapeutics (NASDAQ:ABEO) Must Use Its Cash Wisely

Price target decreased to US$4.50

High number of new directors

Here's Why Abeona Therapeutics (NASDAQ:ABEO) Can Manage Its Debt Despite Losing Money

Abeona Therapeutics Inc. Activates Second Clinical Trial Site in EB-101 Pivotal Phase 3 Viital Study for Recessive Dystrophic Epidermolysis Bullosa

Price target decreased to US$4.67

Abeona Therapeutics Inc.(NasdaqCM:ABEO) dropped from Russell 3000E Value Index

Abeona Therapeutics shares rise after letter to stockholders

Despite Lacking Profits Abeona Therapeutics (NASDAQ:ABEO) Seems To Be On Top Of Its Debt

President notifies of intention to sell stock

Independent Director Paul Mann Just Sold A Bunch Of Shares In Abeona Therapeutics Inc. (NASDAQ:ABEO)

Independent Director recently sold US$310k worth of stock

Independent Director exercised options and sold US$342k worth of stock